Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
WALTHAM, Mass., Jan. 03, 2017 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that William Heiden, chief executive officer, will present at the 35th Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2017 at 11:30 a.m. Pacific Time (2:30 p.m. Eastern Time), in San Francisco, California.
A live audio webcast of the presentation and the following breakout session will be accessible through the Investors section of the AMAG website at www.amagpharma.com. A replay of the webcast will be archived on the website until February 11, 2017.
About AMAG
AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Our products support the health of patients in the areas of maternal health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine. For additional company information, please visit www.amagpharma.com.
AMAG Pharmaceuticals, Inc. Contact: Christi Waarich Associate Director, Investor Relations 617-498-7638
